Proteomics International establishes world class Clinical Advisory Board 
promarkerd.com/clinical-advisory-board

Comprises highly-respected physicians specialising in diabetes and kidney 
disease care from the United States, Europe and Australia

New advisory board offers doctors' viewpoint in commercialisation of the 
PromarkerD blood test for the prediction of diabetic kidney disease
Doctors will ultimately order PromarkerD for diabetes patients with the 
advisory board able to provide specific and tailored advice from the voice of 
the customer perspective

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) 
is pleased to announce it has assembled a team of world leading clinicians 
specialising in nephrology and endocrinology to advise the Company on its 
clinical and commercial initiatives towards a successful launch of the 
PromarkerD test for diabetic kidney disease to physicians globally.

logo: https://mma.prnewswire.com/media/1679695/PILL_logo_Logo.jpg
logo:https://mma.prnewswire.com/media/1679696/pro_promarker_d_logo_tag_pos_color
_rgb_Logo.jpg

The clinicians—from the United States, Europe and Australia—are global experts 
in diabetes technology and care, and influential key opinion leaders (KOLs) in 
their respective fields. Together, they form a world class clinical advisory 
board to offer expert opinion on the best strategies for the market rollout of 
PromarkerD from a doctor's viewpoint.

The engagement of the Clinical Advisory Board builds upon a powerful clinical 
utility study that demonstrated the PromarkerD predictive test for diabetic 
kidney disease (DKD) can help inform doctors' treatment decisions and improve 
clinical outcomes for patients with type 2 diabetes [ASX 18 Oct 21]. Ultimately 
it is physicians that will order the PromarkerD test for their patients, and 
generate sales for Proteomics International.

Proteomics International Managing Director Dr Richard Lipscombe said, "Our new 
Clinical Advisory Board will provide a great insight into what doctors, being 
the end users of the product, regard as the key topics for the successful 
rollout of PromarkerD globally, so it's critical to have their perspective."

Proteomics International Chief Commercialisation Officer Vik Malik said, "We 
are excited with the recruitment of world-class clinical thought leaders in the 
fields of endocrinology and nephrology to serve as our global brand ambassadors 
and provide validation towards our clinical and commercial initiatives." 

"Wide adoption of PromarkerD testing could inform doctors' treatment decisions 
to help avoid end-stage interventions such as dialysis and kidney transplant in 
patients with type 2 diabetes, and this offers potentially significant benefit 
to patient quality of life and cost savings for healthcare systems. We are 
looking forward to our KOLs providing specific and tailored advice from the 
voice of the customer perspective to assist the rollout of the PromarkerD test 
to the world," he said.

The Clinical Advisory Board comprises seven highly-respected physicians, 
researchers and thought leaders, from some of the world's top hospitals and 
universities specialising in the care of diabetes and its complications.

Authorised by the Board of Proteomics International Laboratories Ltd (ASX.PIQ).

SOURCE  Proteomics International